Digital Biomarkers Market Size (2024 - 2029)

The digital biomarkers market is projected to experience significant expansion over the forecast period, driven by the increasing number of clinical trials and advancements in technology. The rising prevalence of chronic diseases globally is expected to enhance the adoption of digital biomarkers for remote patient monitoring. Innovations in wearables and software for vital sign detection are further boosting demand. The integration of sensor data with patient-reported outcomes and real-world sources is facilitating the development of standardized digital biomarkers, increasing confidence among stakeholders. Despite these growth drivers, challenges such as high product costs and data security concerns may impede market expansion.

Market Size of Digital Biomarkers Industry

Digital Biomarkers Market Summary
Study Period 2019 - 2029
Market Size (2024) USD 3.64 Billion
Market Size (2029) USD 9.02 Billion
CAGR (2024 - 2029) 19.90 %
Fastest Growing Market Asia-Pacific
Largest Market North America

Major Players

Digital Biomarkers Market Major Players

*Disclaimer: Major Players sorted in no particular order

Digital Biomarkers Market Analysis

The Digital Biomarkers Market size is estimated at USD 3.64 billion in 2024, and is expected to reach USD 9.02 billion by 2029, growing at a CAGR of 19.90% during the forecast period (2024-2029).

The major factors driving market growth include the growing number of clinical trials and technological advancements in digital biomarkers.

The increasing prevalence of chronic diseases in developing countries and developed countries is anticipated to support the use of digital biomarkers for remote patient monitoring. According to the Centers for Disease Control and Prevention, the percentage of coronary heart disease for adults aged 18 and over in the United States was 4.9% in 2022.

Moreover, market players' introduction of innovative and easy-to-use wearables and software to detect various vital signs is augmenting the demand for digital biomarkers. For instance, in November 2022, Shimmer Research launched its Verisense Digital Health Panel (DHP) to provide clinical researchers with unprocessed, real-world sensor data, enhancing their insights.

The sensor data will be integrated with patient-reported outcomes and various real-world sources, such as tokenized medical records, claims, and pharmacy data. This will facilitate the development of standardized digital biomarkers and endpoints, enhancing confidence and trust among regulators, payors, and patients, thereby boosting market growth.

The increasing number of clinical trials, the growth in research investments, and the development of various therapeutics to manage chronic conditions are expected to drive the demand for digital tools, including digital biomarkers. According to clinicaltrials.gov, 20,189 clinical trials were active in June 2024. The large number of ongoing clinical trials is accountable for the surge in demand for digital biomarkers.

Therefore, owing to the factors mentioned above, the market is anticipated to witness growth over the forecast period. However, high product costs and data security concerns are expected to hinder market growth.

Digital Biomarkers Industry Segmentation

Digital biomarkers are digital devices such as portables, wearables, implantables, or digestibles used to collect objective, quantifiable physiological and behavioral data. The data collected is used mainly to understand health-related outcomes.

The digital biomarkers market is segmented by type, clinical practice, therapeutic area, end user, and geography. By type, the market is segmented into data collection tools and data integration tools. By clinical practice, the market is segmented into monitoring digital biomarkers, diagnostic digital biomarkers, predictive and prognostic digital biomarkers, and other clinical practices. By therapeutic area, the market is segmented into cardiovascular and metabolic disorders, respiratory disorders, neurological disorders, musculoskeletal disorders, and other therapeutic areas. By end user, the market is segmented into pharmaceutical companies, healthcare providers, payers, and other end users. By geography, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the values (USD) for all the above segments.

By Type
Data Collection Tools
Data Integration Tools
By Clinical Practice
Monitoring Digital Biomarkers
Diagnostic Digital Biomarkers
Predictive and Prognostic Digital Biomarkers
Others
By Therapeutic Area
Cardiovascular and Metabolic Disorders
Respiratory Disorders
Neurological Disorders
Musculoskeletal Disorders
Others
By End User
Pharmaceutical Companies
Healthcare Providers
Payers
Others
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Digital Biomarkers Market Size Summary

The digital biomarkers market is poised for substantial growth, driven by the increasing prevalence of chronic diseases and advancements in technology. The market is experiencing a surge in demand due to the rising number of clinical trials and the introduction of innovative wearables and software designed to monitor vital signs. These developments are facilitating remote patient monitoring and enhancing the development of standardized digital biomarkers, which are crucial for gaining the trust of regulators, payors, and patients. Despite challenges such as high product costs and data security concerns, the market is expected to expand significantly, with the monitoring digital biomarkers segment anticipated to witness prominent growth. This segment is particularly driven by the need to monitor patients with chronic conditions, including cardiovascular and respiratory disorders, which are prevalent in both developed and developing countries.

North America is expected to maintain a significant share of the digital biomarkers market, supported by the high prevalence of chronic diseases and a robust number of clinical trials in the region. The availability of advanced technological products and the presence of key market players further bolster market growth. The competitive landscape is semi-consolidated, with several international and local companies, such as Akili Inc., ActiGraph LLC, and Biogen, playing pivotal roles. Collaborations and partnerships among these companies, like the one between Indivi and Biogen, are enhancing digital biomarker platforms for clinical trials, indicating a trend towards increased adoption and integration of digital biomarkers in healthcare.

Explore More

Digital Biomarkers Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Increasing Prevalence of Chronic Diseases

      2. 1.2.2 Growing Number of Clinical Trials

      3. 1.2.3 Technological Advancements in Digital Biomarkers

    3. 1.3 Market Restraints

      1. 1.3.1 High Product Cost

      2. 1.3.2 Data Security Concerns

    4. 1.4 Porter's Five Force Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD)

    1. 2.1 By Type

      1. 2.1.1 Data Collection Tools

      2. 2.1.2 Data Integration Tools

    2. 2.2 By Clinical Practice

      1. 2.2.1 Monitoring Digital Biomarkers

      2. 2.2.2 Diagnostic Digital Biomarkers

      3. 2.2.3 Predictive and Prognostic Digital Biomarkers

      4. 2.2.4 Others

    3. 2.3 By Therapeutic Area

      1. 2.3.1 Cardiovascular and Metabolic Disorders

      2. 2.3.2 Respiratory Disorders

      3. 2.3.3 Neurological Disorders

      4. 2.3.4 Musculoskeletal Disorders

      5. 2.3.5 Others

    4. 2.4 By End User

      1. 2.4.1 Pharmaceutical Companies

      2. 2.4.2 Healthcare Providers

      3. 2.4.3 Payers

      4. 2.4.4 Others

    5. 2.5 Geography

      1. 2.5.1 North America

        1. 2.5.1.1 United States

        2. 2.5.1.2 Canada

        3. 2.5.1.3 Mexico

      2. 2.5.2 Europe

        1. 2.5.2.1 Germany

        2. 2.5.2.2 United Kingdom

        3. 2.5.2.3 France

        4. 2.5.2.4 Italy

        5. 2.5.2.5 Spain

        6. 2.5.2.6 Rest of Europe

      3. 2.5.3 Asia-Pacific

        1. 2.5.3.1 China

        2. 2.5.3.2 Japan

        3. 2.5.3.3 India

        4. 2.5.3.4 Australia

        5. 2.5.3.5 South Korea

        6. 2.5.3.6 Rest of Asia-Pacific

      4. 2.5.4 Middle East and Africa

        1. 2.5.4.1 GCC

        2. 2.5.4.2 South Africa

        3. 2.5.4.3 Rest of Middle East and Africa

      5. 2.5.5 South America

        1. 2.5.5.1 Brazil

        2. 2.5.5.2 Argentina

        3. 2.5.5.3 Rest of South America

Digital Biomarkers Market Size FAQs

The Digital Biomarkers Market size is expected to reach USD 3.64 billion in 2024 and grow at a CAGR of 19.90% to reach USD 9.02 billion by 2029.

In 2024, the Digital Biomarkers Market size is expected to reach USD 3.64 billion.

Digital Biomarkers Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)